## Abstract A recent whole‐genome association study identified a strong association between polymorphisms in the prostate stem cell antigen (PSCA) gene and stomach cancer risk. In this case‐control study, we aimed to validate this association, and further to explore environmental factors possibly i
Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a japanese population
✍ Scribed by Shintaro Narita; Norihiko Tsuchiya; Lizhong Wang; Shinobu Matsuura; Chikara Ohyama; Shigeru Satoh; Kazunari Sato; Osamu Ogawa; Tomonori Habuchi; Tetsuro Kato
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 81 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A high fat intake has been associated with prostate cancer risk, and gene polymorphisms of lipoprotein lipase (LPL) play an important role in plasma lipoprotein metabolism. We herein analyzed the association of LPL gene polymorphisms with the risk of prostate cancer in a Japanese population. Three single nucleotide polymorphisms (SNPs) of LPL designated as Ser447stop, __Hind__III and __Pvu__II were genotyped by the polymerase chain reaction‐restriction fragment length polymorphism method in 273 prostate cancer patients, 205 benign prostatic hyperplasia (BPH) patients and 230 male controls. The men with the CG + GG genotypes of the Ser447stop polymorphism had an increased risk of prostate cancer compared to those with the CC genotype [age‐adjusted odds ratio (aOR) = 1.625; 95% CI = 1.068–2.471; p = 0.023]. Furthermore, the increased risk associated with the CG + GG genotypes was more strongly observed in patients with high‐grade cancers (aOR = 2.843; 95% CI = 1.252–6.458; p = 0.039) or metastatic diseases (aOR = 2.300; 95% CI = 1.042–5.074; p = 0.013), whereas the risk was not significant in those with low‐ to intermediate‐grade cancers or nonmetastatic diseases. In the __Hind__III and __Pvu__II polymorphisms, there was no significant difference between the prostate cancer patients and the controls, and no significant results as for tumor grade and stage. None of the 3 polymorphisms showed any association with the risk of BPH. Our results suggest that the LPL Ser447stop polymorphism is a common genetic modifier for the development of prostate cancer, particularly that of high‐grade and/or high‐stage, in a Japanese population. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
CYP17 encodes the enzyme cytochrome P-450c17␣, which mediates both 17␣-hydroxylase and 17,20-lyase in the steroid biosynthesis pathway. A polymorphism in the 5 promoter region of the CYP17 gene has been described. Steroid hormones, especially androgens, are believed to play a key role in the etiolog
## Abstract The __HPC2__/__ELAC2__ gene may be associated with hereditary/familial prostate cancer (PCa). Two common missense variants (Ser217Leu and Ala541Thr) have been reported in the gene. We performed mutational, allelotyping and expression analyses and a molecular epidemiological study to cla
## Abstract CYP1A1 is likely to play an important role in the etiology of CaP through its function in activating environmental procarcinogens and catalyzing the oxidative metabolites of estrogens. To test the hypothesis that genetic polymorphisms in the __CYP1A1__ gene may be associated with the ri
## Abstract __p73__, a structural and functional homologue of __p53__, shares some p53‐like tumor suppressor activity but also possesses oncogenic activity. Therefore, __p73__ plays an important role in modulating cell‐cycle control and apoptosis. A potentially functional dinucleotide polymorphism,